Design, synthesis and biological evaluation of novel quinazoline-derived EGFR/HER-2 dual-target inhibitors bearing a heterocyclic-containing tail as potential anti-tumor agents

被引:2
|
作者
Hao, Shuang [1 ]
Wang, Jia-hui [1 ]
Hou, Liang [1 ]
Liang, Jing-wei [1 ,2 ]
Yan, Jing-han [1 ]
Niu, Yi-fan [1 ]
Li, Xin-yang [1 ,3 ]
Sun, Qi [1 ]
Meng, Fan-hao [1 ]
机构
[1] China Med Univ, Sch Pharm, Shenyang 110122, Peoples R China
[2] Hainan Med Univ, Sch Pharm, Haikou 571199, Peoples R China
[3] China Med Univ, Shengjing Hosp, Dept Pharm, Shenyang 110004, Peoples R China
基金
中国国家自然科学基金;
关键词
Dual-target inhibitors; EGFR; HER-2; Heterocyclic-containing tail approach; Breast cancer; GROWTH-FACTOR RECEPTOR; ACQUIRED-RESISTANCE; EGFR INHIBITORS; LUNG CANCERS; CELL-LINES; IN-VITRO; AMPLIFICATION; MUTATIONS; MECHANISM;
D O I
10.1016/j.bioorg.2024.107686
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series of novel quinazoline-derived EGFR/HER-2 dual-target inhibitors were designed and synthesized by heterocyclic-containing tail approach. The inhibitory activities against four human epidermal growth factor receptor (HER) isozymes (EGFR, HER-2, HER-3 and HER-4) of all new compounds so designed were investigated in vitro. Compound 12k was found to be the most effective and rather selective dual-target inhibitor of EGFR and HER-2 with inhibitory constant (IC50) values of 6.15 and 9.78 nM, respectively, which was more potent than the clinical used agent Lapatinib (IC50 = 8.41 and 9.41 nM). Meanwhile, almost all compounds showed excellent antiproliferative activities against four cancer cell models (A549, NCI-H1975, SK-BR-3 and MCF-7) and low damage to healthy cells. Among them, compound 12k also exhibited the most prominent antitumor activity. Moreover, the hit compound 12k could bind to EGFR and HER-2 stably in molecular docking and dynamics studies. The following wound healing assay revealed that compound 12k could inhibit the migration of SK-BR-3 cells. Further studies found that compound 12k could arrest cell cycle in the G0/G1 phase and induce SK-BR-3 cells apoptosis. Notably, compound 12k could effectively inhibit breast cancer growth with little toxicity in the SK-BR-3 cell xenograft model. Taken together, in vitro and in vivo results disclosed that compound 12k had high drug potential as a dual-target inhibitor of EGFR/HER-2 to inhibit breast cancer growth.
引用
收藏
页数:19
相关论文
共 40 条
  • [1] Design, synthesis, and biological evaluation of novel quinoline-based EGFR/HER-2 dual-target inhibitors as potential anti-tumor agents
    Al-Wahaibi, Lamya H.
    El-Sheref, Essmat M.
    Tawfeek, Hendawy N.
    Abou-Zied, Hesham A.
    Rabea, Safwat M.
    Braese, Stefan
    Youssif, Bahaa G. M.
    RSC ADVANCES, 2024, 14 (45) : 32978 - 32991
  • [2] Synthesis and biological evaluation of new series of quinazoline derivatives as EGFR/HER2 dual-target inhibitors
    Jiao, Xiaoyu
    Zhang, Qing
    Zhang, Yue
    Shao, Junlan
    Ding, Lei
    Tang, Chunlei
    Feng, Bainian
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2022, 67
  • [3] Design, synthesis and biological evaluation of novel hybrids of quinazoline derivatives and phenylsulfonylfuroxan as potential anti-tumor agents
    Wang, Hao
    Chi, Lingling
    Yu, Fuqing
    Dai, Honglin
    Gao, Chao
    Si, Xiaojie
    Wang, Zhengjie
    Liu, Limin
    Zhao, Peirong
    Zhu, Yingnan
    Liu, Hongmin
    Zhang, Qiurong
    MEDICINAL CHEMISTRY RESEARCH, 2023, 32 (08) : 1749 - 1769
  • [4] Design, synthesis and biological evaluation of novel hybrids of quinazoline derivatives and phenylsulfonylfuroxan as potential anti-tumor agents
    Hao Wang
    Lingling Chi
    Fuqing Yu
    Honglin Dai
    Chao Gao
    Xiaojie Si
    Zhengjie Wang
    Limin Liu
    Peirong Zhao
    Yingnan Zhu
    Hongmin Liu
    Qiurong Zhang
    Medicinal Chemistry Research, 2023, 32 : 1749 - 1769
  • [5] Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors
    Lv, Peng-Cheng
    Zhou, Chang-Fang
    Chen, Jin
    Liu, Peng-Gang
    Wang, Kai-Rui
    Mao, Wen-Jun
    Li, Huan-Qiu
    Yang, Ying
    Xiong, Jing
    Zhu, Hai-Liang
    BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 18 (01) : 314 - 319
  • [6] Design, synthesis and biological evaluation of sulfur-containing tetrahydroxanthones as potential anti-tumor agents
    Zheng, Huimin
    Wang, Youyi
    Ren, Yitao
    Wang, Xueying
    Sui, Lu
    Xu, Hongxi
    Zheng, Changwu
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2025, 121
  • [7] Design, synthesis and biological evaluation of pyrazolyl-thiazolinone derivatives as potential EGFR and HER-2 kinase inhibitors
    Qiu, Ke-Ming
    Wang, Hai-Hong
    Wang, Li-Ming
    Luo, Yin
    Yang, Xian-Hui
    Wang, Xiao-Ming
    Zhu, Hai-Liang
    BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (06) : 2010 - 2018
  • [8] Design, synthesis and biological evaluation of pyrazolyl-nitroimidazole derivatives as potential EGFR/HER-2 kinase inhibitors
    Tao, Xiang-Xiang
    Duan, Yong-Tao
    Chen, Long-Wang
    Tang, Dan-Jie
    Yang, Meng-Ru
    Wang, Peng-Fei
    Xu, Chen
    Zhu, Hai-Liang
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (02) : 677 - 683
  • [9] Synthesis and biological evaluation of novel oxadiazole derivatives: A new class of thymidine phosphorylase inhibitors as potential anti-tumor agents
    Shahzad, Sohail Anjum
    Yar, Muhammad
    Bajda, Marek
    Jadoon, Bushra
    Khan, Zulfiqar Ali
    Naqvi, Syed Ali Raza
    Shaikh, Ahson Jabbar
    Hayat, Khizar
    Mahmmod, Adeem
    Mahmood, Nasir
    Filipek, Slawomir
    BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (03) : 1008 - 1015
  • [10] Design, synthesis and biological evaluation of novel peptides as potential agents with anti-tumor and multidrug resistance-reversing activities
    Bo Zhang
    Wei Shi
    Jieming Li
    Chen Liao
    Mingxue Li
    Wenlong Huang
    Hai Qian
    Amino Acids, 2017, 49 : 1355 - 1364